- Alnylam’s 1Q revenue reached $594.2 million, showing a 20% increase year-over-year and surpassing the estimated $578.4 million.
- The adjusted loss per share was 1.0 cent, a significant improvement from a previous loss of 16 cents per share, better than the estimated loss of 35 cents per share.
- The overall loss per share decreased to 44 cents compared to last year’s 52 cents, outperforming the estimated loss of 91 cents per share.
- Net product revenues rose to $468.5 million, an increase of 28% year-over-year, exceeding the projected $462 million.
- Givlaari net product revenues totaled $67 million, a 15% increase year-over-year, slightly below the estimate of $68.5 million.
- Oxlumo net product revenues were $42 million, slightly down by 1.5% year-over-year, missing the estimate of $45.6 million.
- Collaboration revenue dropped by 16% year-over-year to $99.2 million but still surpassed the estimate of $92.1 million.
- Operating expenses amounted to $576.1 million, a 7.1% increase year-over-year, but came in lower than the estimated $701 million.
- Cash and cash equivalents reached $1.02 billion, marking a 50% increase year-over-year and exceeding the projected $943.6 million.
- Adjusted R&D expenses were $241.3 million, below the estimate of $259.7 million.
- There are 24 ‘buy’ ratings for the company’s stock, 8 ‘hold’ ratings, and 1 ‘sell’ rating.
Alnylam Pharmaceuticals on Smartkarma
Independent analysts on Smartkarma are buzzing about Alnylam Pharmaceuticals, with Baptista Research leading the charge. In their report, “Alnylam Pharmaceuticals: The Groundbreaking ATTR Amyloidosis Expansion That’s Turning Heads!” Baptista Research highlights the company’s strong financial performance in the fourth quarter of 2024. Alnylam reported net product revenues exceeding $1.6 billion, a 33% growth from the previous year, driven by the uptake of therapeutics for hereditary transthyretin mediated (hATTR) amyloidosis and other rare diseases.
Further, in their analysis titled “Alnylam Pharmaceuticals: Pipeline Expansion In Neurodegenerative Diseases As A Pivotal Factor Driving Growth! – Major Drivers,” Baptista Research underscores the company’s success in Q3 2024. Alnylam Pharmaceuticals showcased a 34% year-over-year increase in global net product revenue, totaling $420 million. This growth was primarily fueled by the strong performance of its TTR franchise, which alone generated $309 million, marking a 34% increase from the previous year.
A look at Alnylam Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alnylam Pharmaceuticals Inc., an early-stage therapeutics company, is positioned for long-term growth and momentum based on its Smartkarma Smart Scores. With a high growth score of 4 and strong momentum score of 5, the company is showing positive signs for future expansion and market performance. Alnylam’s focus on developing technology to silence disease-causing genes is expected to drive its growth in the pharmaceutical sector.
Although Alnylam Pharmaceuticals has lower scores in value and dividend factors (2 and 1 respectively), the company’s overall outlook remains positive with a solid resilience score of 2. This resilience, coupled with its growth and momentum scores, suggests that the company is well-equipped to navigate challenges and capitalize on opportunities in the long run. Investors may find Alnylam Pharmaceuticals an attractive prospect for potential growth and market performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
